Journal Mobile Options
Table of Contents
Vol. 126, No. 2, 2001
Issue release date: October 2001
Section title: Original Paper
Int Arch Allergy Immunol 2001;126:135–139
(DOI:10.1159/000049504)

A Th1-Inducing Adjuvant, MPL®, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines

Wheeler A.W.a · Marshall J.S.b · Ulrich J.T.c
aAllergy Therapeutics Ltd, Worthing, UK, bDalhousie University, Halifax, Canada and cCorixa Corporation, Hamilton, Mont., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 11/30/2001
Issue release date: October 2001

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Monophosphoryl lipid A (MPL®) is a detoxified derivative of the lipopolysaccharide (LPS) moiety of Salmonella minnesota R595, which has retained immunostimulatory activities. MPL® has been administered to many subjects in clinical trials as an adjuvant component of infectious disease vaccines and is currently a component of a licensed cancer vaccine, Melacine® (Corixa Inc., Schering Plough). MPL® has, in particular, been shown to promote Th1-type antigen specific responses. L-tyrosine is a depot adjuvant which is fully metabolisable and has been successfully employed in allergy vaccines for a number of years. Methods: Mice were immunised with MPL® adjuvant in conjunction with separate preparations of either ovalbumin or glutaraldehyde-modified ragweed pollen extract both coprecipitated with L-tyrosine. The specific antibody isotypes IgG1, IgG2a, IgG2b and also IgE were measured. Rats received booster injections of keyhole limpet haemocyanin (KLH) in conjunction with MPL® adjuvant following priming with KLH in alum alone. KLH-specific antibody responses were measured. Results: It was shown that a combination of L-tyrosine and MPL® were synergistic in enhancing murine antigen specific IgG antibody responses without enhancing antigen specific IgE responses. Furthermore, this adjuvant combination promoted strong IgG2 antigen specific responses indicative of a Th1 directed response. In KLH sensitised rats, treatment with MPL® was shown to prevent a secondary IgE antibody response when injected with booster injections of antigen. Conclusions: Immunisation of mice with two different antigens adsorbed to L-tyrosine induced a Th1-skewed primary response when in conjunction with MPL® adjuvant which also generally enhances a specific IgG response. Incorporation of MPL® adjuvant in the immunisation of rats prevented a secondary specific IgE response. These results suggest that the employment of this new adjuvant in clinical allergy vaccination formulations may result in an improved efficacy which could be utilised in various ways to improve compliance.

© 2001 S. Karger AG, Basel


  

Author Contacts

Correspondence to: Dr. Alan W. Wheeler
Allergy Therapeutics Ltd.
Dominion Way
Worthing, West Sussex BN14 8SA (UK)
Tel. +44 1903 844 724, Fax +44 1903 844 744, E-Mail alan.wheeler@allergytherapeutics.com

  

Article Information

MPL® is a registered trademark of Corixa Corporation, Seattle, Wash., USA. All other trademarks referred to in this document are the property of their respective owners.

Received: Received: February 1, 2001
Accepted after revision: May 30, 2001
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 2, Number of References : 18

  

Publication Details

International Archives of Allergy and Immunology
Founded 1950

Vol. 126, No. 2, Year 2001 (Cover Date: October 2001)

Journal Editor: D. Kraft, Vienna
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information:http://www.karger.com/journals/iaa


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 11/30/2001
Issue release date: October 2001

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.